Effect of N-3 polyunsaturated fatty acid supplementation in pregnancy: the Nuheal trial.
In this placebo controlled, randomised, double blind trial, pregnant women received from the 20th week of gestation onwards either 500 mg docosahexaenoic acid (DHA), 400 mg 5-methyl-tetra-hydro-folate (5-MTHF), or placebo, or a combination of 500 mg DHA and 400 mg 5-MTHF. The dietary supplements were well tolerated; the dropout rates did not differ significantly in the active arms of the study (10% to 19%) from that seen in the placebo group (13%). DHA supplementation resulted in significant enhancement of the contribution of DHA to maternal, placental and venous cord blood lipids.
Decsi
Tamás
T
Department of Paediatrics, University of Pécs, Pécs, Hungary.
Campoy
Cristina
C
Koletzko
Berthold
B
D000328:Adult; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000097:blood; D004311:Double-Blind Method; D004912:Erythrocytes / Q000737:chemistry; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D050356:Lipid Metabolism; D039382:Maternal Nutritional Physiological Phenomena; D008431:Maternal-Fetal Exchange; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011262:Pregnancy Trimester, Second / Q000097:blood; D011263:Pregnancy Trimester, Third / Q000097:blood; D013763:Tetrahydrofolates / Q000008:administration & dosage / Q000097:blood
D015525:Fatty Acids, Omega-3; D013763:Tetrahydrofolates; D004281:Docosahexaenoic Acids; C005984:5-methyltetrahydrofolate